Click to login and read the full article.
Don’t have access? Click here to request a demo
Alternatively, Call a member of the team to discuss membership options
US and Overseas: +1 646-931-9045
UK: 0207 139 1600
Abstract
Venture capitalists who invest in the first round of start-up companies eventually have to decide which companies they will continue to fund. A typical investor in these early stages, especially in medical device and bio/pharmaceutical companies, will expect to write off 20% to 30% of all investments. It is a much more efficient use of capital when this writeoff occurs after just one investment, when the dollars at risk are usually modest. In this article, the author describes the issues involved in making follow-on investing decisions and suggests how the process can work more effectively for venture capital partnerships and for portfolio companies.
- © 2012 Pageant Media Ltd
Don’t have access? Click here to request a demo
Alternatively, Call a member of the team to discuss membership options
US and Overseas: +1 646-931-9045
UK: 0207 139 1600